Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression
Brain Medicine · 17.11.2026 · 1-5
DOI: 10.61373/bm026k.0069 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain Medicine, erschienen am 17.11.2026. Verfasst von Cheng-Ta Li. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Depression
Abstract (Originalsprache)
Cheng-Ta Li, MD, PhD, has devoted his career to a deceptively simple question: why do patients with apparently similar depression follow such different paths, and can psychiatry learn to tell them apart before treatment begins? A psychiatrist and neuroscientist, he is Professor at the School of Medicine and Institute of Brain Science of National Yang Ming Chiao Tung University and directs the Precision Depression Intervention Center (PreDIC) at Taipei Veterans General Hospital. Opened in June 2022 as Taiwan's first center devoted to precision care for depression, PreDIC concentrates on treatment-resistant depression (TRD) and has since recorded more than 20,000 patient visits. Its guiding idea is that treatment resistance is not a yes-or-no verdict but a continuum, one that can be staged by severity and degree of refractoriness. To give that idea clinical form, Dr. Li and his team built AI-PreDIC®, a patented platform that reads clinical data alongside EEG and FDG-PET to estimate where each patient stands, an early step toward bringing TRD staging into routine practice. The center rests on a long record of research. His 2014 randomized sham-controlled trial in Brain was among the first large trials of theta-burst stimulation for refractory depression, and his group went on to help establish theta-burst stimulation, repetitive transcranial magnetic stimulation, and low-dose ketamine and esketamine in Taiwanese psychiatry. His population studies have shown, among other findings, that TRD runs strongly in families. Today his attention turns to the brain networks through which specific treatments act, to TMS-EEG measures of cortical excitation and inhibition, to imaging biomarkers and machine learning that might match patients to therapies, and to emerging treatments such as psychedelics. The author of more than 300 peer-reviewed publications, he has carried this science into patents, technology transfer, clinical consensus, and professional training. He is also founding President of the Taiwanese Society of Brain Stimulation and has served as Secretary General of the Asian College of Neuropsychopharmacology. In this Genomic Press Interview, he reflects on the patients and the early skepticism that drew him to brain stimulation, the mentors who shaped his scientific values, and his hope of moving depression care from trial and error toward precision.
Zitieren
APA
Li, C. (2026). Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression. Brain Medicine, 1-5. https://doi.org/10.61373/bm026k.0069
Vancouver
Li C. Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression. Brain Medicine. 2026:1-5. doi:10.61373/bm026k.0069
BibTeX
@article{Li2026,
author = {Li, Cheng-Ta},
title = {Cheng-Ta Li: Using AI to guide biology-informed precision therapeutics across the continuum of treatment resistance in depression},
journal = {Brain Medicine},
year = {2026},
pages = {1--5},
doi = {10.61373/bm026k.0069}
}
EUVIMED